Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
MNPR Stock Chart & Stats
$82.58
-$0.61(-2.42%)
At close: 4:00 PM EST
$82.58
-$0.61(-2.42%)
Day’s Range― - ―
52-Week Range$16.26 - $105.00
Previous CloseN/A
Volume23.12K
Average Volume (3M)118.35K
Market Cap
$594.94M
Enterprise ValueN/A
Total Cash (Recent Filing)$39.50B
Total Debt (Recent Filing)$80.37M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding7,204,394
10 Day Avg. Volume172,360
30 Day Avg. Volume118,353
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)0.00
P/FCF Ratio-13.02
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$110.33Price Target Upside33.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsMonopar Therapeutics is primarily focused on developing an innovative treatment for Wilson disease.
Efficacy And Market PotentialPooled phase 2/3 data shows serum creatinine levels within normal ranges over six years, reinforcing confidence in ALXN1840's favorable benefit/risk profile.
Market OpportunityThe Wilson's Disease market in the US and EU5 could be worth more than $2.5 billion, indicating significant revenue potential for Monopar Therapeutics.
Bears Say
Clinical Data ConcernsThere are competing beliefs on ALXN1840's effectiveness, with some experts questioning the sufficiency of clinical data for long-term safety.
FDA And Validation UncertaintyThere is still a modest risk that the FDA may ask for another copper balance study for further validation.
Regulatory RisksThere are regulatory risks associated with the stock, which may affect its future performance.
Monopar Therapeutics Inc News
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $16.26 and its highest was $105.00 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Monopar Therapeutics Inc’s market cap is $594.94M.
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 126 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.433 by -$0.047.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 7,204,394 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.433. Following the earnings report the stock price went up 14.55%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
Monopar Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.33 (33.60% Upside)
$110.33 (33.60% Upside)
Blogger Sentiment
Bullish
MNPR Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $35.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
378.72%
12-Months-Change
Fundamentals
Return on Equity
-59.38%
Trailing 12-Months
Asset Growth
650.24%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
MNPR Stock 12 Month Forecast
Average Price Target
$110.33
▲(33.60% Upside)
Technical Analysis
Cardiff Oncology
―
Vanda
―
Verastem
―
Mereo Biopharma Group Plc
―
Silence Therapeutics
―
Ownership Overview
53.18% Insiders
2.29% Mutual Funds
18.31% Other Institutional Investors
21.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---